Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Catalyst Pharmaceuticals Inc maintains a gross margin of 76.71%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 40.52%, while the net margin is 34.53%. These profitability ratios, combined with a Return on Equity (ROE) of 25.49%, provide a clear picture of how effectively CPRX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CPRX competes directly with industry leaders such as IDYA and TVTX. With a market capitalization of $2.92B, it holds a significant position in the sector. When comparing efficiency, CPRX's gross margin of 76.71% stands against IDYA's 100.00% and TVTX's 98.03%. Such benchmarking helps identify whether Catalyst Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
